Sorafenib-Induced Acute Pancreatitis
Downloads
References
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90. [PMID 18650514]
Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505-12. [PMID 16636341]
Amar S, Wu KJ, Tan WW. Sorafenib-induced pancreatitis. Mayo Clin Proc 2007; 82:521. [PMID 17418082]
Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J 2007; 100:909-11. [PMID 17902294]
Banks PA, Freeman ML, Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006; 101:2379-400. [PMID 17032204]
Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007; 5:648-61. [PMID 17395548]
ASHP guidelines on adverse drug reaction monitoring and reporting. American Society of Hospital Pharmacy. Am J Health Syst Pharm 1995; 52:417-9. [PMID 7757870]
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. National Cancer Institute 2009. (http://evs.nci.nih.gov/ftp1/CTCAE/About.html)
Bayer AG. Leverkusen, Germany. Nevaxar (sorafenib). Highlights of prescribing information. (http://www.univgraph.com/bayer/inserts/nexavar.pdf)
Copyright (c) 2010 Hamid Saadati, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.